Cambridge Isotope Laboratories, Inc. (CIL) is the world’s leading producer of stable isotopes and stable isotope-labeled compounds. With over 400 employees and laboratories in four countries, CIL specializes in the process of labeling biochemical and organic compounds with highly enriched, stable (nonradioactive) isotopes of carbon, hydrogen, nitrogen and oxygen. Our chemists substitute common atoms (e.g., 1H, 12C, 14N, 16O) with rare, highly valued isotopes (e.g., 2H or D, 13C, 15N, 18O) so that the final product can be readily measured or traced using mass spectrometry (MS) or nuclear magnetic resonance (NMR). CIL’s products are utilized in laboratories, medical, government and academic research centers and health care facilities worldwide. We are proud that CIL products have contributed to medical advancements in cancer research, new-drug development, environmental analysis, genomics and proteomics, and medical diagnostic research. In the past decade, as the fields of proteomics and metabolomics have developed as leading techniques for determining biomarkers for disease presence, progression and the monitoring of therapeutic response, CIL has worked closely with industry leaders and researchers to provide the stable isotope-labeled tools needed for improved quantitation of complex systems.
Nuclear magnetic resonance (NMR) spectroscopy provides information regarding the structure and dynamics for protein, RNA and DNA at the atomic level. These biomolecules may be studied individually or in the presence of ligands or other biomolecules. Determination of the three-dimensional structure of macromolecules and their complexes is vital for rational drug design and expanding knowledge within the field of mechanistic biology. The term “biomolecular NMR” refers to the use of NMR to study biological compounds in vivo or under conditions which best mimic in vivo conditions. Although most cytosolic proteins are relatively easy to study, membrane proteins require lipophilic environments for stability and function and thus are typically studied in micelles, lipid bilayers, cellular membranes and living cells. NMR generally lacks the sensitivity to detect useful signals from unlabeled sample, therefore biomolecules are often required to be enriched in 13C and/or 15N for analyses. Deuterium is often incorporated to simplify spectra or to alter relaxation effects so that the necessary spectroscopic information may be acquired. Over the years, advances in isotope-labeling strategies have expanded the size of macromolecules and the types of detailed information available for study.
Over the past decade, there have been vast improvements in the detection and quantification of proteins, metabolites and potential biomarkers using mass spectrometry-based methodologies. Advances in bioinformatics and instrumentation, combined with the use of stable isotopes, have furthered the development, sensitivity and accuracy of quantitative methods.
CIL offers a comprehensive listing of our isotope-enriched products that can be utilized for a wide range of mass spectrometry-based fields of research, including proteomics, metabolism, metabolic, clinical diagnostics and environmental analysis.
CIL continues to maintain a leadership role in developing new products to study proteins, protein turnover, metabolic disorders and environmental contaminants. It has been through our partnerships and close relationships with our customers over the past 30 years that we have been able to significantly expand our product offering in order to assist this community in the advancement of their studies utilizing stable-isotope-labeled compounds as a tool in mass spectrometry.
CIL products have contributed to medical advancements in cancer research, new-drug development, environmental analysis, genomics and proteomics, and medical diagnostic research. In the past decade, as the fields of proteomics and metabolomics have developed as leading techniques for determining biomarkers for disease presence, progression and the monitoring of therapeutic response, CIL has worked closely with industry leaders and researchers to provide the stable isotope-labeled tools needed for improved quantitation of complex systems.
Through our collaborations with environmental testing laboratories, regulatory agencies and research institutions around the world, CIL has developed numerous products to assist a wide range of testing applications. You will find more than 3,000 products developed specifically for trace and ultra-trace analysis by isotope dilution mass spectrometry. As new technology and methodologies advance, CIL maintains a leadership role in developing new standards and standard mixtures to keep pace with these new procedures. You will find throughout this website many new products developed in various solvents for use in not only new GC-MS applications, but also LC-MS methods that continue to gain importance as an integral part of the environmental testing laboratory.
Mass spectrometry (MS) used as a routine tool in the clinic is becoming more and more of a reality every day. It has been demonstrated that MS-based assays decrease errors and lead to better clinical outcomes as compared to traditional standards of care.1 Cambridge Isotope Laboratories, Inc. recognizes the need to provide high-quality internal standards to aid in the development of robust methods suitable for clinical care. This diverse catalog of stable isotope-labeled products ranges from small molecule standards to complete proteomic solutions. Products are manufactured and tested to meet the highest chemical and isotopic purity specifications commercially available, allowing researchers and clinicians to focus on what really matters – improving patient care.
Nuclear medicine specialists use safe, painless and cost-effective techniques to image the body and treat disease. Nuclear medicine imaging is unique, because it provides doctors with information about both structure and function. It is a way to gather medical information that would otherwise be unavailable, require surgery or necessitate more expensive diagnostic tests. Nuclear medicine imaging procedures often identify abnormalities very early in the progress of a disease long before many medical problems are apparent with other diagnostic tests.